SCHEMBL1702307

SCHEMBL1702307

O=C1CCC(=O)N1OS(=O)(=O)O

nearest known ligand 0.50

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
PARL Q9H300 4/20 0.50
CA2 P00918 2/20 0.32
CA12 O43570 1/20 0.32
CA1 P00915 1/20 0.32
CA9 Q16790 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28981837 0.98 PARL (0.48) PARLCA2CA12CA1CA9
Pyridine SCHEMBL9065176 0.83 PARL (0.50) PARL
SCHEMBL28411329 0.79 PARL (0.54) PARLCA2CA12CA1CA9
SCHEMBL9064898 0.79 PARL (0.34) PARL
SCHEMBL64828 0.75 PARL (0.50) PARLCA2CA12CA1CA9
SCHEMBL29748565 0.74 PARL (0.46) PARLCA2CA12CA1CA9
SCHEMBL12813400 0.73 PARL (0.41) PARL
SCHEMBL7261683 0.72 PARL (0.43) PARL
SCHEMBL15271986 0.72 PARL (0.35) PARL
SCHEMBL10651115 0.71 PARL (0.31) PARL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114805310-A Fluorescent compounds containing hydroxy-substituted triazines and methods of making the same 佰爱特有限公司 2022-07-29 CN claimed
CN-109758675-A A kind of self-healing medical gel 青岛中腾生物技术有限公司 2019-05-17 CN claimed
CN-109646709-A A kind of medical hemostatic closed material of degradable absorption 青岛中腾生物技术有限公司 2019-04-19 CN claimed
US-5556976-A FORMING WET AND DRY RESILIENT CELLULOSE FIBERS WITH HIGH ABSORBENCY, BULK AND WET AND DRY RESILIENCY FOR PAPER TOWELS, DIAPERS AND SANITARY PRODUCTS JEWELL RICHARD A (US) 1996-09-17 US claimed
US-12440448-B2 Powder, wound-covering material, adhesion prevention material, hemostatic material, and production method for powder NATIONAL INSTITUTE FOR MATERIALS SCIENCE (JP) 2025-10-14 US disclosed
US-20250134965-A1 ANTI-ADHESIVE MATERIAL, AND METHOD FOR PRODUCING ANTI-ADHESIVE MATERIAL NATIONAL INSTITUTE FOR MATERIALS SCIENCE (JP) 2025-05-01 US disclosed
EP-4506021-A1 ANTI-ADHESIVE MATERIAL, AND METHOD FOR PRODUCING ANTI-ADHESIVE MATERIAL National Institute for Materials Science (JP) 2025-02-12 EP disclosed
EP-4032557-B1 BIOLOGICAL TISSUE ADHESIVE SHEET , BIOLOGICAL TISSUE REINFORCING MATERIAL KIT, AND METHOD FOR PRODUCING BIOLOGICAL TISSUE ADHESIVE SHEET NAT INST MATERIALS SCIENCE (JP) 2024-12-25 EP disclosed
US-12171810-B2 Angiogenesis promoter and therapeutic method NATIONAL INSTITUTE FOR MATERIALS SCIENCE (JP) 2024-12-24 US disclosed
EP-4032558-B1 BIOLOGICAL TISSUE ADHESIVE SHEET, BIOLOGICAL TISSUE REINFORCING MATERIAL KIT, AND METHOD FOR MANUFACTURING BIOLOGICAL TISSUE ADHESIVE SHEET NAT INST MATERIALS SCIENCE (JP) 2024-11-06 EP disclosed
EP-3862016-B1 ANGIOGENESIS PROMOTER FOR USE IN TREATING A PERIPHERAL ARTERY DISEASE NAT INST MATERIALS SCIENCE (JP) 2024-04-24 EP disclosed
WO-2023181563-A1 ANTI-ADHESIVE MATERIAL, AND METHOD FOR PRODUCING ANTI-ADHESIVE MATERIAL 国立研究開発法人物質・材料研究機構 2023-09-28 WO disclosed
US-6680311-B1 ANTICARCINOGENIC, ANTITUMOR AND ANTIPROLIFERATIVE AGENTS ELI LILLY AND COMPANY 2004-01-20 US disclosed
EP-0934065-A4 PHARMACEUTICAL COMPOUNDS LILLY CO ELI (US) 2000-10-11 EP disclosed
EP-0934065-A1 PHARMACEUTICAL COMPOUNDS ELI LILLY AND COMPANY (US) 1999-08-11 EP disclosed
CN-1215164-A Gene expression variation and protein positioning high-output analysis system HAN XIAOLIANG (CN) 1999-04-28 CN disclosed
WO-1998008505-A1 PHARMACEUTICAL COMPOUNDS ELI LILLY AND COMPANY (US) 1998-03-05 WO disclosed
US-5556976-A FORMING WET AND DRY RESILIENT CELLULOSE FIBERS WITH HIGH ABSORBENCY, BULK AND WET AND DRY RESILIENCY FOR PAPER TOWELS, DIAPERS AND SANITARY PRODUCTS JEWELL RICHARD A (US) 1996-09-17 US disclosed
US-5366591-A Cyclic N-sulfatoimide WEYERHAEUSER 1994-11-22 US disclosed
WO-1993014261-A1 METHOD FOR CROSSLINKING INDIVIDUALIZED CELLULOSE FIBRES WEYERHAEUSER COMPANY (US) 1993-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12171810-B2 Angiogenesis promoter and therapeutic method HDGF, VEGFA, EGLN2 PARL 4584/4885CA2 1227/4885CA12 1658/4885
US-12440448-B2 Powder, wound-covering material, adhesion prevention material, hemostatic material, and production method for powder COL2A1, COL1A1, F12 PARL 3697/4885CA2 1959/4885CA12 1744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.